Home › Funds › DIADEMA PARTNERS LP › RLMD
DIADEMA PARTNERS LP position in RLMD
RELMADA THERAPEUTICS INC · Health Care
DIADEMA PARTNERS LP reported holding 361,367 shares of RLMD (RELMADA THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$2.5M, representing 0.54% of its reported portfolio and ranking #45 among its reported holdings. DIADEMA PARTNERS LP has disclosed RLMD holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How DIADEMA PARTNERS LP's RLMD position evolved
DIADEMA PARTNERS LP first disclosed a stake in RLMD in Q4 2025 at 389,395 shares (US$1.9M). The position peaked in Q2 2026 at 361,367 shares, worth US$2.5M. Across 3 filings, DIADEMA PARTNERS LP increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 361,367 shares valued at US$2.5M — an increase of 160,525 shares quarter over quarter.. Notable position changes include a 48% trim in Q1 2026 (shares were roughly flat over the following quarter), a 80% increase in Q2 2026 (shares fell 46% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 389.39K | $1.88M | New |
| Q1 2026 | 200.84K | $1.40M | Reduce |
| Q2 2026 | 361.37K | $2.50M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About RLMD and 13F data
RLMD (RELMADA THERAPEUTICS INC) is a Health Care company. 76 other funds we track also report a position in RLMD — the largest reported positions include Squadron Capital Management LLC (US$50.9M), Venrock Adviser, LLC (US$47.4M), Spruce Street Capital LP (US$44.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding RLMD
- Squadron Capital Management LLC 7.35M sh · $50.86M · Q2 2026
- Venrock Adviser, LLC 6.84M sh · $47.36M · Q2 2026
- Spruce Street Capital LP 6.39M sh · $44.23M · Q2 2026
- Jones Hill Capital LP 3.66M sh · $25.29M · Q2 2026
- Ikarian Capital, LLC 2.15M sh · $14.87M · Q2 2026
- STEMPOINT CAPITAL LP 1.46M sh · $10.10M · Q2 2026
- Commodore Capital LP 1.43M sh · $9.86M · Q2 2026
- Sio Capital Management, LLC 1.00M sh · $6.94M · Q2 2026
- Opaleye Management Inc. 935.00K sh · $6.47M · Q2 2026
- Boxer Capital Management, LLC 842.11K sh · $5.83M · Q2 2026
- GREAT POINT PARTNERS LLC 842.11K sh · $5.83M · Q2 2026
- Knott David M Jr 451.00K sh · $3.12M · Q2 2026
More on DIADEMA PARTNERS LP
FAQ
How long has DIADEMA PARTNERS LP held RLMD?
DIADEMA PARTNERS LP has disclosed RLMD holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
What is DIADEMA PARTNERS LP's current position in RLMD?
As of Q2 2026, DIADEMA PARTNERS LP holds 361.37K shares of RLMD (RELMADA THERAPEUTICS INC), valued at $2.50M, representing 0.54% of its reported portfolio and ranking #45.
Has DIADEMA PARTNERS LP been buying or selling RLMD?
In the latest 13F filing (Q2 2026), DIADEMA PARTNERS LP increased its position in RLMD. The position peaked in Q2 2026 at 361.37K shares.
Which other funds hold RLMD?
Other major institutional holders of RLMD include Squadron Capital Management LLC, Venrock Adviser, LLC, Spruce Street Capital LP, among 76 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.